Výsledky vyhľadávania - "Isabel Arrillaga-Romany"

Author Correction: Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial

Autori: Ingo K. Mellinghoff Min Lu Patrick Y. Wen a ďalší

Zdroj: Nat Med

Predmety: Author Correction

Chemotherapy-induced reversal of ciltacabtagene autoleucel–associated movement and neurocognitive toxicity

Autori: Charlotte E. Graham Won-Ho Lee Hadley R. Wiggin a ďalší

Zdroj: Blood. 142:1248-1252

Predmety: Cognition, Humans, Antineoplastic Agents, Multiple Myeloma, Immunotherapy, Adoptive, 3. Good health

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/37467494

Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort.

Autori: McFaline-Figueroa, J. Ricardo Sun, Lu Youssef, Gilbert C. a ďalší

Zdroj: Nature Communications; 12/30/2024, Vol. 15 Issue 1, p1-9, 9p

Predmety: IMMUNE checkpoint inhibitors, MEDICAL sciences, NATURAL immunity, CANCER genes, GLIOBLASTOMA multiforme

Prognostic Features of Recurrent Midline and H3 K27M-Mutant Glioma.

Autori: Bagley, Stephen J. Umemura, Yoshie Mendez, Joe S. a ďalší

Zdroj: Cancers; Jul2025, Vol. 17 Issue 13, p2107, 12p

Predmety: BRAIN tumor treatment, GLIOMA treatment, RISK assessment, GLIOMAS, RESEARCH funding, SCIENTIFIC observation, TREATMENT effectiveness, CANCER patients, RETROSPECTIVE studies, MULTIVARIATE analysis, DESCRIPTIVE statistics, HISTONES, ONCOGENES, RESEARCH, MEDICAL records, ACQUISITION of data, GENETIC mutation, CONFIDENCE intervals, DISEASE progression, OVERALL survival, BRAIN tumors, EVALUATION

Geografický termín: UNITED States

Current status of antiangiogenic therapies for glioblastomas

Autori: Patrick Y. Wen David A. Reardon Isabel Arrillaga-Romany

Zdroj: Expert Opinion on Investigational Drugs. 23:199-210

Predmety: 03 medical and health sciences, 0302 clinical medicine, Brain Neoplasms, Drug Resistance, Neoplasm, 13. Climate action, Animals, Humans, Angiogenesis Inhibitors, Glioblastoma, 3. Good health

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/24320142
https://www.tandfonline.com/doi/full/10.1517/13543784.2014.856880
https://pubmed.ncbi.nlm.nih.gov/24320142/
https://www.ncbi.nlm.nih.gov/pubmed/24320142

Performance of a Hospital Pathway for Patients With a New Single Brain Mass

Autori: Joshua N. Goldstein William T. Curry Susann J. Jarhult a ďalší

Zdroj: Journal of Oncology Practice. 15:e211-e218

Predmety: Adult, Aged, 80 and over, Male, Brain Diseases, Biopsy, Disease Management, Middle Aged, Hospitals, 3. Good health, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Critical Pathways, Electronic Health Records, Humans, Female, Emergency Service, Hospital, Tomography, X-Ray Computed, 10. No inequality, Aged

Prístupová URL adresa: https://ascopubs.org/doi/pdfdirect/10.1200/JOP.17.00098
https://pubmed.ncbi.nlm.nih.gov/30681891
https://pubmed.ncbi.nlm.nih.gov/30681891/
https://www.ncbi.nlm.nih.gov/pubmed/30681891
https://ascopubs.org/doi/pdfdirect/10.1200/JOP.17.00098
https://ascopubs.org/doi/full/10.1200/JOP.17.00098

Diffuse midline glioma, H3K27-altered: Illuminating the dark side of the moon.

Autori: Dun, Matthew D Odia, Yazmin Arrillaga-Romany, Isabel

Zdroj: Neuro-Oncology; 2024 Supplement, Vol. 26, pS89-S91, 3p

ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma.

Autori: Arrillaga-Romany, Isabel Lassman, Andrew McGovern, Susan L a ďalší

Zdroj: Neuro-Oncology; 2024 Supplement, Vol. 26, pS173-S181, 9p

Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.

Autori: Odia, Yazmin Hall, Matthew D Cloughesy, Timothy Francis a ďalší

Zdroj: Neuro-Oncology; 2024 Supplement, Vol. 26, pS165-S172, 8p

Developing a Virtual Equity Hub: Adapting the Tumor Board Model for Equity in Cancer Care.

Autori: Irwin, Kelly E Ko, Naomi Walsh, Elizabeth P a ďalší

Zdroj: Oncologist; Jul2022, Vol. 27 Issue 7, p518-524, 7p, 3 Diagrams, 1 Chart

Predmety: TUMOR treatment, TUMOR diagnosis, HEALTH services accessibility, CANCER treatment, COMMUNITY health services, INTERPROFESSIONAL relations, ACADEMIC medical centers, SAFETY-net health care providers, SOCIAL determinants of health, MENTAL health services, HEALTH impact assessment, CANCER patient medical care, CLINICAL trials, HUMAN research subjects, PILOT projects, BREAST tumors, CANCER patients, INSTITUTIONAL cooperation, TELEMEDICINE, PATIENT-centered care, NERVOUS system tumors, MEDICAL research, VIDEOCONFERENCING, COMMUNICATION, ORGANIZATIONAL change, HEALTH equity, EVIDENCE-based medicine, SPECIALTY hospitals, HEALTH care teams

Abstracts to the 42^nd Annual Meeting of the Japan Society for Neuro-Oncology.

Zdroj: Neuro-Oncology Advances; 2024 Supplement, Vol. 6, preceding piv1-iv28, 140p

Long-term outcomes and late toxicity of adult medulloblastoma treated with combined modality therapy: A contemporary single-institution experience.

Autori: Saraf, Anurag Yock, Torunn I Niemierko, Andrzej a ďalší

Zdroj: Neuro-Oncology; Dec2022, Vol. 24 Issue 12, p2180-2189, 10p

ACTR-33. TUMOR TISSUE PENETRATION AND PHARMACODYNAMICS OF ONC201 IN ADULT RECURRENT GLIOBLASTOMA PATIENTS.

Autori: Arrillaga-Romany, Isabel Odia, Yazmin Allen, Joshua a ďalší

Zdroj: Neuro-Oncology; 2018 Supplement, Vol. 20, pvi18-vi19, 2p

IDH-mutant glioma: A new IDH1 inhibitor moves forward.

Autori: Miller, Julie J Arrillaga-Romany, Isabel

Zdroj: Neuro-Oncology; Feb2023, Vol. 25 Issue 2, p337-338, 2p

Imposing Phase II and Phase III Clinical Trials of Targeted Drugs for Glioblastoma: Current Status and Progress.

Autori: Wang, Yaning Chen, Wanqi Shi, Yixin a ďalší

Zdroj: Frontiers in Oncology; 9/9/2021, Vol. 12, p1-13, 13p

Predmety: CLINICAL drug trials, BRAIN tumors, CENTRAL nervous system tumors, INTRACRANIAL tumors, OVERALL survival, GLIOBLASTOMA multiforme, IMMUNOTHERAPY, PROGNOSIS, TUMOR grading

Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma.

Autori: Lim-Fat, Mary Jane Song, Kun Wei Iorgulescu, J. Bryan a ďalší

Zdroj: Journal of Neuro-Oncology; May2021, Vol. 152 Issue 3, p515-522, 8p

TERT and DNMT1 expression predict sensitivity to decitabine in gliomas.

Autori: Park, Jong-Whi Sahm, Felix Steffl, Bianca a ďalší

Zdroj: Neuro-Oncology; Jan2021, Vol. 23 Issue 1, p76-87, 12p

Demonstrated efficacy and mechanisms of sensitivity of ONC201: H3K27M-mutant diffuse midline glioma in the spotlight.

Autori: Arrillaga-Romany, Isabel Miller, Julie J

Zdroj: Neuro-Oncology; Jun2024, Vol. 26 Issue 6, p991-992, 2p

Biological activity of weekly ONC201 in adult recurrent glioblastoma patients.

Autori: Arrillaga-Romany, Isabel Odia, Yazmin Prabhu, Varun V a ďalší

Zdroj: Neuro-Oncology; Jan2020, Vol. 22 Issue 1, p94-102, 9p

Accelerated progression of IDH mutant glioma after first recurrence.

Autori: Miller, Julie J Loebel, Franziska Juratli, Tareq A a ďalší

Zdroj: Neuro-Oncology; May2019, Vol. 21 Issue 5, p669-677, 9p